

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> (use as many sheets as necessary)				Complete if Known	
				Application Number	11/709,045
				Filing Date	November 10, 2000
				First Named Inventor	M. Rigdon Lentz
				Group Art Unit	1647
				Examiner Name	Lorraine Spector
Sheet	1	of	4	Attorney Docket Number	LEN 102

[illegible][illegible]

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Please type a plus sign (+) inside this box →


 PTO/SB/08A (10-95)
 Approved for use through 10/31/99. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	11/709,045		
		Filing Date	November 10, 2000		
		First Named Inventor	M. Rigdon Lentz		
		Group Art Unit	1647		
		Examiner Name	Lorraine Spector		
Sheet	2	of	4	Attorney Docket Number	LEN 102

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ADOLF and FRÜHBEIS, "Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity.", <i>Cytokine</i> , 4(3):180-184 (1992).	
		BJORNBERG, et al., "Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms", <i>Lymphokine Cytokine Res.</i> , 13(3):203-11 (1994).	
		CSEHI, et al., "Tumor necrosis factor (TNF) interferes with insulin signaling through the p55 TNF receptor death domain", <i>Biochem Biophys Res Commun</i> , 329(1):397-405 (2005).	
		FENG, "Regulatory roles and molecular signaling of TNF family members in osteoclasts", <i>Gene</i> , 350(1):1-13 (2005).	
		GADDUCCI, et al., "Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer", <i>Gynecol Oncol</i> , 58(2):184-8 (1995).	
		GRELL, et al., "The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor", <i>Proc Natl Acad Sci U S A</i> , 95(2):570-5 (1998).	
		GROSEN, et al., "Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy", <i>Gynecol Oncol</i> , 50(1):68-77 (1993).	
		HASEGAWA, et al., "Increased soluble tumor necrosis factor receptor levels in the serum of elderly people", <i>Gerontology</i> , 46(4):185-8 (2000).	
		HOLTMANN, et al., "The emerging distinct role of TNF-receptor 2 (p80) signaling in chronic inflammatory disorders", <i>Arch Immunol Ther Exp (Warsz)</i> , 50(4):279-88 (2002).	
		JABLONSKA, et al., "Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients", <i>Eur Cytokine Netw</i> , 9(2):155-9 (1998).	
		LIU, et al., "Molecular mechanism of TNF signaling and beyond", <i>Cell Res</i> , 15(1):24-7 (2005).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	11/709,045		
		Filing Date	November 10, 2000		
		First Named Inventor	M. Rigdon Lentz		
		Group Art Unit	1647		
		Examiner Name	Lorraine Spector		
Sheet	3	of	4	Attorney Docket Number	LEN 102

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MACALLAN, et al., "Development of a novel TNF alpha ligand-receptor binding assay for screening NATCHEM Libraries", <i>J Recept Signal Transduct Res</i> , 17(1-3):521-9 (1997).	
		MAIER, et al., "Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study", <i>J Neurotrauma</i> , 22(7):822-35 (2005).	
		MUC-WIERZGON, et al., "Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer", <i>J Exp Clin Cancer Res</i> , 22(2):171-8 (2003).	
		NOPHAR, et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor", <i>EMBO J</i> , 9(10):3269-78 (1990).	
		ONSRUD, et al., "Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer", <i>Gynecol Oncol</i> , 57(2):183-7 (1995).	
		ONSRUD, et al., "Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer", <i>Tumour Biol</i> , 17(2):90-6 (1996).	
		RZYMSKI, et al., "Serum tumor necrosis factor alpha receptors p55/p75 ratio and ovarian cancer detection", <i>J Gynaecol Obstet</i> , 88(3):292-8 (2005).	
		SERWIN, et al., "[Soluble tumor-necrosis-factor-alpha receptor type-1 as a marker of activity of psoriasis vulgaris and effects of its treatment]", <i>Przegl Lek</i> , 62(2):95-7 (2005).	
		SERWIN, et al., "Soluble tumor necrosis factor alpha receptor type 1 in psoriasis patients treated with narrowband ultraviolet B" <i>Photodermatol Photoimmunol Photomed</i> , 21(4):210-1 (2005).	
		SHAI, et al., "A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes", <i>Diabetes Care</i> , 28(6):1376-82 (2005).	
		SUKHIKH, et al., "Disorders in cytokine gene expression in endometrial hyperplasia and effect of hormone therapy", <i>Bull Exp Biol Med.</i> , 139(2):235-7 (2005).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Receipt date: 09/04/2009

09709045 - GAU: 1647

Please type a plus sign (+) inside this box →


 PTO/SB/08A (10-96)
 Approved for use through 10/31/99. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	11/709,045		
		Filing Date	November 10, 2000		
		First Named Inventor	M. Rigdon Lentz		
		Group Art Unit	1647		
		Examiner Name	Lorraine Spector		
Sheet	4	of	4	Attorney Docket Number	LEN 102

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		TESAROVA, et al., "Soluble TNF and IL-2 receptors in patients with breast cancer", <i>Med Sci Monit</i> , 6(4):661-7 (2000).	
		THEISS, et al., "Tumor Necrosis Factor (TNF) {alpha} Increases Collagen Accumulation and Proliferation in Intestinal Myofibroblasts via TNF Receptor 2", <i>J Biol Chem</i> , 280(43):36099-109 (2005).	
		WAJANT, et al., "Tumor necrosis factor signaling", <i>Cell Death Differ</i> , 10(1):45-65 (2003).	
		WOZEL, "[Etanercept An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis.]" <i>Hautarzt</i> , 56(9):819-830 (2005).	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Examiner's Signature	/Cherie M. Woodward/	Date Considered	11/08/2011
-------------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+